RESUMO
BACKGROUND: Non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) may be eligible for targeted immunotherapies. Literature does not currently estimate direct costs associated with this population. We aimed to identify the total direct costs associated with PD-L1 positive stage IV NSCLC treated with immunotherapy. METHODS: Using progression-free survival, overall survival, treatment-related serious adverse events leading to hospitalization, and end-of-life resource use, we estimated costs for one year of treatment in this incidence-based study. Data were obtained from online databases, guideline recommendations, clinical trials, and proprietary market share data. We summed the costs of PD-L1 immunohistochemistry (IHC) tests, drugs, hospitalizations, and deaths associated with treatment, estimating the overall cost-of-illness for stage IV NSCLC in the United States in 2021. RESULTS: An estimated 22,711 patients in the US had stage IV NSCLC treated with PD-L1 immunotherapy in 2021. Total 2021 costs were estimated at $3.01 billion. Drugs (including immunotherapy, second-line chemotherapy, and other oncology drugs) accounted for nearly 97% ($2.91 billion) of the total. CONCLUSIONS: PD-L1 positive stage IV NSCLC treatment is a costly condition with annual direct medical costs of $3.01 billion. The primary cost driver was immunotherapy, making up 74.6% of the total cost.